These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28104306)

  • 1. Midterm and one-year outcome of amphilimus polymer free drug eluting stent in patients needing short dual antiplatelet therapy. Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTer rEgistry).
    Godino C; Chiarito M; Donahue M; Testa L; Colantonio R; Cappelletti A; Monello A; Magni V; Milazzo D; Parisi R; Nicolino A; Moshiri S; Fattori R; Aprigliano G; Palloshi A; Caramanno G; Montorfano M; Bedogni F; Briguori C; Margonato A; Colombo A
    Int J Cardiol; 2017 Mar; 231():54-60. PubMed ID: 28104306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients needing short dual antiplatelet therapy. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry).
    Godino C; Beneduce A; Ferrante G; Ielasi A; Pivato CA; Chiarito M; Cappelletti A; Perfetti G; Magni V; Prati E; Falcone S; Pierri A; De Martini S; Montorfano M; Parisi R; Rutigliano D; Locuratolo N; Anzuini A; Tespili M; Margonato A; Benassi A; Briguori C; Fabbiocchi F; Reimers B; Bartorelli A; Colombo A
    Int J Cardiol; 2019 Sep; 290():52-58. PubMed ID: 30917900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Antiplatelet Therapy for 6 Months vs 12 Months After New-generation Drug-eluting Stent Implantation: Matched Analysis of ESTROFA-DAPT and ESTROFA-2.
    de la Torre Hernández JM; Oteo Domínguez JF; Hernández F; García Camarero T; Abdul-Jawad Altisent O; Rivero Crespo F; Cascón JD; Zavala G; Gimeno F; Arrebola Moreno AL; Andraka L; Gómez Menchero A; Bosa F; Carrillo X; Sánchez Recalde Á; Alfonso F; Pérez de Prado A; López Palop R; Sanchis J; Diarte de Miguel JA; Jiménez Navarro M; Muñoz L; Ramírez Moreno A; Tizón Marcos H;
    Rev Esp Cardiol (Engl Ed); 2015 Oct; 68(10):838-45. PubMed ID: 26072146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year clinical outcome of amphilimus polymer-free drug-eluting stent in diabetes mellitus patients: Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTre rEgistry).
    Colombo A; Godino C; Donahue M; Testa L; Chiarito M; Pavon AG; Colantonio R; Cappelletti A; Monello A; Magni V; Milazzo D; Parisi R; Nicolino A; Moshiri S; Fattori R; Aprigliano G; Palloshi A; Caramanno G; Montorfano M; Bedogni F; Margonato A; Briguori C
    Int J Cardiol; 2016 Jul; 214():113-20. PubMed ID: 27060269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Camaro C; Damen SA; Brouwer MA; Kedhi E; Lee SW; Verdoia M; Barbieri L; Rognoni A; van T Hof AW; Ligtenberg E; de Boer MJ; Suryapranata H; De Luca G
    Am Heart J; 2016 Aug; 178():37-44. PubMed ID: 27502850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCI.
    Piccolo R; Calabrò P; Varricchio A; Baldi C; Napolitano G; De Simone C; Mauro C; Stabile E; Caiazzo G; Tesorio T; Boccalatte M; Tuccillo B; Bottiglieri G; Russolillo E; Di Lorenzo E; Carrara G; Cassese S; Leonardi S; Biscaglia S; Costa F; McFadden E; Heg D; Franzone A; Stefanini GG; Capodanno D; Esposito G
    Am Heart J; 2023 Nov; 265():153-160. PubMed ID: 37572785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer-coated sirolimus-eluting coronary stents: Insight from the I-LOVE-IT 2 trial.
    Qi J; Li Y; Li J; Jing Q; Xu K; Gao C; Ma L; Zhang Z; Xu B; Han Y
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):555-564. PubMed ID: 28318138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial.
    Kedhi E; Verdoia M; Suryapranata H; Damen S; Camaro C; Benit E; Barbieri L; Rasoul S; Liew HB; Polad J; Ahmad WA; Zambahari R; Lalmand J; van der Schaaf RJ; Koh TH; Timmermans P; Dilling-Boer D; Veenstra LF; Van' T Hof AW; Lee SW; Roolvink V; Ligtenberg E; Postma S; Kolkman EJ; Brouwer MA; Dudek D; De Luca G
    Atherosclerosis; 2021 Mar; 321():39-44. PubMed ID: 33639478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of dual antiplatelet therapy and outcomes after coronary stenting with the Genous™ bio-engineered R stent™ in patients from the e-HEALING registry.
    Damman P; Klomp M; Silber S; Beijk MA; Ribeiro EE; Suryapranata H; Wójcik J; Sim KH; Tijssen JG; de Winter RJ;
    Catheter Cardiovasc Interv; 2012 Feb; 79(2):243-52. PubMed ID: 21542121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
    Gilard M; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berland J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Endresen K; Benamer H; Kiss RG; Ungi I; Boschat J; Morice MC
    J Am Coll Cardiol; 2015 Mar; 65(8):777-786. PubMed ID: 25461690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of real-world patients treated with an amphilimus polymer-free stent versus new generation everolimus-eluting stents.
    Panoulas VF; Latib A; Naim C; Sato K; Ielasi A; Tespili M; Godino C; Testa L; Bedogni F; Colombo A
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1168-76. PubMed ID: 26269415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of over-2-year dual antiplatelet therapy on the rate of major adverse cardiac and cerebral events for everolimus-eluting stent implantation: The landmark analysis from Tokyo-MD PCI registry.
    Ueshima D; Ashikaga T; Yoshikawa S; Sasaoka T; Hatano Y; Kurihara K; Maejima Y; Isobe M
    J Cardiol; 2017 Jun; 69(6):815-822. PubMed ID: 27692568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Gwon HC; Hahn JY; Park KW; Song YB; Chae IH; Lim DS; Han KR; Choi JH; Choi SH; Kang HJ; Koo BK; Ahn T; Yoon JH; Jeong MH; Hong TJ; Chung WY; Choi YJ; Hur SH; Kwon HM; Jeon DW; Kim BO; Park SH; Lee NH; Jeon HK; Jang Y; Kim HS
    Circulation; 2012 Jan; 125(3):505-13. PubMed ID: 22179532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy)-diabetes substudy.
    Tarantini G; Nai Fovino L; Tellaroli P; Chieffo A; Barioli A; Menozzi A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Dominguez JF; Steffanon L; Presbitero P; Pucci E; Fraccaro C; Mauri J; Giustino G; Sardella G; Colombo A
    Int J Cardiol; 2016 Mar; 207():168-76. PubMed ID: 26803236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.
    Colombo A; Chieffo A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Oteo Dominguez JF; Steffanon L; Tarantini G; Presbitero P; Menozzi A; Pucci E; Mauri J; Cesana BM; Giustino G; Sardella G
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2086-97. PubMed ID: 25236346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).
    Kim BK; Hong MK; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Kang TS; Park BE; Kang WC; Lee SH; Yoon JH; Hong BK; Kwon HM; Jang Y;
    J Am Coll Cardiol; 2012 Oct; 60(15):1340-8. PubMed ID: 22999717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents.
    Kandzari DE; Barker CS; Leon MB; Mauri L; Wijns W; Fajadet J; Mehran R
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1119-28. PubMed ID: 22017938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    Silber S; Kirtane AJ; Belardi JA; Liu M; Brar S; Rothman M; Windecker S
    Eur Heart J; 2014 Aug; 35(29):1949-56. PubMed ID: 24510638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry.
    Buszman PP; Orlik B; Trela B; Milewski K; Kozlowski M; Pruski M; Drzewiecki J; Peppas A; Granada JF; Kaluza GL; Buszman PE
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E155-62. PubMed ID: 23109067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
    Valgimigli M; Borghesi M; Tebaldi M; Vranckx P; Parrinello G; Ferrari R;
    Eur Heart J; 2013 Mar; 34(12):909-19. PubMed ID: 23315904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.